Drug Trial Radar · NCT07774364
Safety and Efficacy of Topical AT-004 1% in Participants With Acne Vulgaris (AV)
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
63
Actual
Start
Feb 2, 2026
Primary completion
Jul 15, 2026
Study completion Jul 29, 2026
Sponsor
- Lead sponsor
- Arctic TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Blueskin AS
- First posted
- Aug 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Double blinded, randomized, placebo-controlled trial to determine the safety and efficacy of topical AT-004 therapy in participants with acne vulgaris, including assessment of reduction in the number of acne lesions and IGA. A PK sub-study will be performed in a subset of participants. Participants with moderate to severe acne vulgaris, aged 18 to 45 years, who are likely to meet inclusion and none of the exclusion criteria will be invited for a screening visit. The study include a screening period, treatment phase with the baseline visit at day 1 and a follow -up visits at week 4, 8 and week 12. All participants will be followed by a follow-up call within 4 weeks from last visit. A total number of 60 participants will be enrolled.
Conditions
- Acne Vulgaris on the Face
Interventions
AT-004Drug
Participants receiving AT-004 topical application
PlaceboDrug
Participants receiving matching placebo topical application
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: 12 weeks
- Laboratory safety parametersTime frame: 12 weeks
- Incidence of inflammatory and non-inflammatory lesionsTime frame: 12 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Sanos Gandrup Clinic
Gandrup, Denmark
Herlev Sanos Clinic
Herlev, Denmark
Sanos Vejle Clinic
Vejle, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.